(P023) Role of Concurrent Systemic Therapy With Adjuvant Radiation Therapy for Locally Advanced Cutaneous Squamous Cell Carcinoma

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Postoperative RT with or without systemic therapy was associated with acceptable disease-related outcomes at 1 year. Outcomes of patients managed with systemic therapy plus RT may be attributable to selection bias, since patients with more advanced disease receive systemic therapy.

Uma Goyal, MD, Nitin Prabhakar, Sun K. Yi, MD; University of Arizona

INTRODUCTION: Despite the prevalence of head and neck cutaneous squamous cell carcinoma (HNcSCC), few randomized trials have evaluated the optimal combination of therapy. Most patients with locally advanced (LA) HNcSCC undergo surgical resection, followed by radiation therapy (RT) with or without systemic therapy (ST). The purpose of our study was to perform an initial retrospective review of 19 patients who were treated for LA-HNcSCC with postoperative RT with or without ST.

METHODS: Nineteen patients with 20 LA-HNcSCCs from 2013–2014, who were treated at our institution with postoperative RT with or without ST, were reviewed. Eligibility was based on recurrent disease, nodal involvement, extensive or named perineural invasion, and bulky (T3/4) primary disease. Endpoints evaluated between groups receiving postoperative RT ± ST included locoregional recurrence (LRR), disease-free survival (DFS), distant metastases–free survival (DMFS), and overall survival (OS). Statistical analysis was performed using Student’s t-test.

RESULTS: All 19 patients were male. Median age was 71 years. Median follow-up was 10 months. All patients were treated with adjuvant RT (45–69.6 Gy in 15–35 fractions). A total of 11 patients received ST and 8 did not. Of those receiving ST, 42% received concurrent platinum-based therapy and 21% received concurrent cetuximab. Those receiving postoperative RT with ST vs without ST had a 9% vs 0% LRR (P = .4), 55% vs 100% DFS (P = .03), 82% vs 100% DMFS (P = .2), and 82% vs 100% OS (P = .2), respectively.

CONCLUSION: Postoperative RT with or without ST was associated with acceptable disease-related outcomes at 1 year. Outcomes of patients managed with ST plus RT may be attributable to selection bias, since patients with more advanced disease receive ST. However, they could also reflect an increased risk of death in patients receiving more intensive treatment. Further prospective clinical studies will be needed to validate outcomes and elucidate differences between LA-HNcSCC patients receiving postoperative RT with or without ST.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Related Content